What is the standard dosing protocol for GHRP-6?

Conventional GHRP-6 dosing is 100-300 mcg 2-3x daily subq via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does GHRP-6's half-life affect dosing?

GHRP-6 has a plasma half-life of ~15-30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3x daily subq dosing at 100-300 mcg per dose explains the typical onset timeline for scheduling and cycle endpoints.

What does GHRP-6 stack well with?

For protocol / scheduling / cycling protocols, GHRP-6 pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from GHRP-6's primary mechanism (Ghrelin-receptor agonist with the most pronounced effect on the central appetite circuit of any GHRP), producing additive or synergistic effects rather than receptor competition.

Is GHRP-6 safe during pregnancy or breastfeeding?

GHRP-6, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ GHRP-6

GHRP-6

Protocol

Scheduling GHRP-6 alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The first-generation GHRP, notable for strong appetite-stimulating effects alongside its GH-releasing action. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Stack SchedulingDaily TimingPeriodised CyclesMaintenance PhaseOff-Time

Key Takeaways

Scheduling lens: GHRP-6's ~15-30 min half-life via subq places it in the multi-daily-dosing bucket.
Mechanism: Ghrelin-receptor agonist with the most pronounced effect on the central appetite circuit of any GHRP.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Ghrelin-receptor agonist with the most pronounced effect on the central appetite circuit of any GHRP. Stimulates GH release and concurrently increases hunger and gastric motility. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for GHRP-6.

Cycle length and off-cycle planning

Standard GHRP-6 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any GHRP-6 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most GHRP-6 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

GHRP-6 with a ~15-30 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 2-3x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Weekly Timing

For weekly timing scheduling, GHRP-6 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Tapered Cycles

The most-asked scheduling question for GHRP-6 in tapered cycles is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Periodised Cycles

Schedule design for GHRP-6 in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Pulse Strategies

For pulse strategies scheduling, GHRP-6 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-300 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	100-300 mcg	2-3x daily SubQ
Maintenance phase	SubQ	70-300 mcg	Ongoing with periodic pauses

Dose timing for GHRP-6 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GHRP-6 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

GHRP-6 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GHRP-6's mechanism in protocol / scheduling / cycling protocols.
GHRP-6 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GHRP-6's mechanism in protocol / scheduling / cycling protocols.
GHRP-6 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with GHRP-6's mechanism in protocol / scheduling / cycling protocols.
GHRP-6 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with GHRP-6's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved

Marked appetite stimulation. Cortisol/prolactin elevation. Avoid if weight gain is undesirable.

Lens-specific safety considerations for protocol / scheduling / cycling use of GHRP-6: Marked appetite stimulation. Cortisol/prolactin elevation. Avoid if weight gain is undesirable. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

GHRP-6 — appetite and GH release

PMID 1518370

Supporting

Ghrelin receptor and GHRP-6 mechanism

PMID 11717269

GHRP-6 vs Related Peptides

Compound	Profile	Onset	Best For
GHRP-6	Growth hormone releasing peptide	~15-30 min	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Daily timing for GHRP-6?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Cycle length and off-cycle period?

Standard cycle for GHRP-6 is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

What is the regulatory status of GHRP-6?

GHRP-6 regulatory status: Unapproved in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Should I cycle GHRP-6?

Standard cycle for GHRP-6 is 8–12 weeks of 2-3x daily subq 100-300 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to GHRP-6's ~15-30 min half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a GHRP-6 Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified GHRP-6 and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 873 Da
Sequence length: 6 aa
Half-life: ~15-30 min
WADA: Banned (S2)
FDA: Unapproved

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-6 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for GHRP-6

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised